Literature DB >> 16083775

Innate immune responses to infection.

Michael F Tosi1.   

Abstract

The human host survives many infectious challenges in the absence of preexisting specific (adaptive) immunity because of the existence of a separate set of protective mechanisms that do not depend on specific antigenic recognition. These antigen-independent mechanisms constitute innate immunity. Antimicrobial peptides are released at epithelial surfaces and disrupt the membranes of many microbial pathogens. Toll-like receptors on epithelial cells and leukocytes recognize a range of microbial molecular patterns and generate intracellular signals for activation of a range of host responses. Cytokines released from leukocytes and other cells exhibit a vast array of regulatory functions in both adaptive and innate immunity. Chemokines released from infected tissues recruit diverse populations of leukocytes that express distinct chemokine receptors. Natural killer cells recognize and bind virus-infected host cells and tumor cells and induce their apoptosis. Complement, through the alternative and mannose-binding lectin pathways, mediates antibody-independent opsonization, phagocyte recruitment, and microbial lysis. Phagocytes migrate from the microcirculation into infected tissue and ingest and kill invading microbes. These innate immune mechanisms and their interactions in defense against infection provide the host with the time needed to mobilize the more slowly developing mechanisms of adaptive immunity, which might protect against subsequent challenges.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083775     DOI: 10.1016/j.jaci.2005.05.036

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  85 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Immunostimulatory activity of snake fruit peel extract on murine macrophage-like J774.1 cells.

Authors:  Sri Wijanarti; Agus Budiawan Naro Putra; Kosuke Nishi; Eni Harmayani; Takuya Sugahara
Journal:  Cytotechnology       Date:  2015-10-19       Impact factor: 2.058

Review 3.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

Review 4.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.

Authors:  Ryuta Sakuma; Amber A Mael; Yasuhiro Ikeda
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

6.  DAF-16-dependent suppression of immunity during reproduction in Caenorhabditis elegans.

Authors:  Sachiko Miyata; Jakob Begun; Emily R Troemel; Frederick M Ausubel
Journal:  Genetics       Date:  2008-02-01       Impact factor: 4.562

7.  Welfare and immune response.

Authors:  L Bonizzi; P Roncada
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

8.  Immunomodulatory activity of acidic polysaccharides isolated from Tanacetum vulgare L.

Authors:  Gang Xie; Igor A Schepetkin; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2007-09-05       Impact factor: 4.932

9.  Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Jun Tian; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

10.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.